Lupus nephritis (SLE glomerulonephritis, ISN/RPS class I-VI)
Bedside summary
Renal involvement in systemic lupus erythematosus, a major driver of SLE morbidity/mortality. Immune-complex glomerulonephritis classified ISN/RPS class I-VI; class III (focal) and IV (diffuse) proliferative disease (and mixed +/- class V membranous) are the aggressive forms requiring prompt immunosuppression, while class V is membranous-pattern nephrotic. Presents with haematuria, proteinuria, hypertension, active sediment, declining GFR and low complement (C3 AND C4) with high anti-dsDNA. Early biopsy-guided therapy preserves kidney function.
Red flags
- Rapidly rising creatinine with active sediment/crescents — aggressive proliferative/crescentic LN, urgent immunosuppression
- Nephritic-nephrotic with hypertension and falling GFR
- Thrombotic microangiopathy features (thrombocytopenia, MAHA) — APS nephropathy or TTP/HUS overlap
- Pulmonary haemorrhage, cerebral lupus, severe cytopenias — life-threatening multisystem flare
- Pregnancy with active lupus nephritis — high-risk, specialist multidisciplinary care
Assessment
Differential diagnosis
- Other proliferative/immune-complex GN (post-infectious, MPGN, IgA)
- ANCA vasculitis / anti-GBM (pauci-immune RPGN)
- Thrombotic microangiopathy (antiphospholipid syndrome nephropathy, TTP/HUS) — may coexist with lupus
- Primary membranous nephropathy (vs lupus class V)
- Drug-induced lupus; chronic kidney disease of other cause
Investigations
- Urine microscopy (dysmorphic RBCs, red/cellular casts) + PCR/ACR; serum albumin, U&E/creatinine/eGFR, BP
- SLE serology: ANA, anti-dsDNA (correlates with renal activity), complement C3 and C4 (both low in active disease), anti-Sm, ENA
- Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta2GPI) — APS nephropathy risk
- FBC (cytopenias), haemolysis screen/blood film (coexistent TMA), CRP/ESR
- Renal biopsy — essential to assign ISN/RPS class, activity and chronicity indices (directs therapy)
- Baseline for immunosuppression: HBV/HCV/HIV, TB screen, pregnancy test, thiopurine methyltransferase (if azathioprine planned)
Management
- Diagnose SLE and perform early renal biopsy to classify (class and activity/chronicity) — this governs treatment intensity
- All patients: hydroxychloroquine (improves renal and overall outcomes), BP control and RAS blockade for proteinuria, statin, sun protection, bone/infection prophylaxis
- Class I/II (minimal/mesangial): treat extrarenal lupus; renoprotection, no intensive renal immunosuppression
- Active class III/IV (+/- V) proliferative disease: start initial immunosuppression with glucocorticoids PLUS either mycophenolate (MMF/MPA analogue) or low-dose IV cyclophosphamide (Euro-Lupus), and add a second agent as triple therapy — belimumab or a calcineurin inhibitor (voclosporin/tacrolimus) — per KDIGO 2024
- Use glucocorticoid-sparing strategy: pulse IV methylprednisolone then a RAPID oral prednisolone taper to minimise steroid toxicity
- Pure class V (membranous): immunosuppression if nephrotic/progressive, with anticoagulation considerations as for membranous nephropathy
- Maintenance (>=3 years): mycophenolate or azathioprine (azathioprine if pregnancy planned) +/- belimumab, continuing hydroxychloroquine; monitor dsDNA/complement, proteinuria and eGFR for flares
- Manage APS/thrombosis, pregnancy planning (teratogen avoidance: MMF/cyclophosphamide/ACEi), and infection prophylaxis (PCP) throughout
Drugs & doses
Disposition
Complications & pitfalls
- Progression to ESKD; flares and chronic proteinuric CKD
- Immunosuppression/steroid toxicity: infection, osteoporosis, avascular necrosis, gonadotoxicity (cyclophosphamide), malignancy
- Thromboembolism (antiphospholipid syndrome)
- Accelerated cardiovascular disease
- Adverse pregnancy outcomes; teratogenicity of several agents
Exam pearls
- Low C3 AND low C4 with high anti-dsDNA points strongly to lupus nephritis (vs post-strep where only C3 falls) — but the biopsy class, activity and chronicity still decide therapy.
- KDIGO 2024 favours TRIPLE therapy for active class III/IV: steroid + mycophenolate (or low-dose cyclophosphamide) PLUS belimumab or voclosporin, with a rapid steroid taper to cut toxicity.
- Hydroxychloroquine is for almost every lupus patient — it improves renal outcomes and reduces flares; do not omit it.
- Switch mycophenolate to azathioprine before a planned pregnancy and stop ACEi/ARB — MMF, cyclophosphamide and RAS blockers are teratogenic.
- Euro-Lupus low-dose IV cyclophosphamide (500 mg x6) is as effective as high-dose with far less toxicity.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.